Avergen and BioSolveIT win PERMIDES Grant to push boundaries of personalized medicine

Martinsried, Germany and Sankt Augustin, Germany, July 25, 2017 — Avergen Pharmaceutical GmbH (APG) and BioSolveIT announce today that they are backed by a PERMIDES grant approval from the European Union to conduct their collaboration in costumizing a drug screening platform.

Research Cooperation

On 31.03.2017 APG signed a cooperation agreement with the Helmholtz Institute in Munich. We are excited to engage in this scientifically challenging project jointly with expirienced scientists from the Helmholtz Institute.

17th GAIN Conference in San Francisco 25-27 August 2017

Dr. Yildiz was part of two industry and academic expert panels discussing carrier paths for German scientists working in North America.

On 23rd Feb. 2017 we received a grant from Bayern Innovativ

Bayern Innovativ is Bavaria's organisation for innovation, technology and knowledge transfer. The grant supports our validation study for the small molecule drug discovery platform.